



Cadila Healthcare Limited

Registered Office : Zydus Tower , Satellite Cross Roads, Ahmedabad - 380015.
Tel. No. (+91-79) 686 8100 Fax No. : (+91-79) 686 2365/66 Website : www.zyduscadila.com

Audited Financial Results for the Quarter ended 31st March, 2006.

CONSOLIDATED						Sr.No.	Particulars	COMPANY				
Rupees in Millions								Rupees in Millions				
For the Nine Months ended on 31st Dec., 2005	Quarter ended 31st March,		Period ended 31st March,					For the Nine Months ended on 31st Dec., 2005	Quarter ended 31st March,		Year ended 31st March,	
	2006	2005	2006	2005					2006	2005	2006	2005
				Comparable [#]	Published							
11577	3501	2433	15078	12744	13051	1	Sales & Income from operations :	10178	2904	2069	13082	11253
488	137	136	625	621	621	A	Gross Sales	486	136	136	622	619
11089	3364	2297	14453	12123	12430	B	Less : Excise Duty	9692	2768	1933	12460	10634
296	96	163	392	349	349	C	Net Sales	292	85	155	377	313
11385	3460	2460	14845	12472	12779	D	Other Income from Operations	9984	2853	2088	12837	10947
45	(9)	0	36	29	29	E	Total sales and other income from operations	329	50	129	379	472
11430	3451	2460	14881	12501	12808	2	Total Income	10313	2903	2217	13216	11419
-167	68	-154	-99	(369)	-361	3	Expenditure :					
4458	1329	988	5787	5154	5201	4	Increase / Decrease [-] in Stock in Trade	(186)	134	(174)	(52)	(293)
1363	441	475	1804	1630	1653	A	Consumption of Materials	4016	1126	931	5142	4604
3510	966	828	4476	3788	3858	B	Staff Cost	1156	373	405	1529	1405
9164	2804	2137	11968	10203	10351	C	Other Expenditure	3010	767	675	3777	3307
2266	647	323	2913	2298	2457	D	Total Expenditure	7996	2400	1837	10396	9023
143	51	40	194	210	210	E	Profit before Interest , Depreciation & Tax	2317	503	380	2820	2396
72	-15	10	57	35	35	6	Interest & Financial Charges	107	41	33	148	172
215	36	50	251	245	245	A	Exchange Rate Fluctuations on Foreign Currency Loans	72	(15)	10	57	30
2051	611	273	2662	2053	2212	B	Total Financial cost	179	26	43	205	202
585	194	180	779	709	716	C	Profit before Depreciation & Tax	2138	477	337	2615	2194
1466	417	93	1883	1344	1496	7	Depreciation & Amortisation	453	163	130	616	566
89	26	31	115	125	125	8	Profit before Tax & Exceptional Items	1685	314	207	1999	1628
1377	391	62	1768	1219	1371	9	Less : Exceptional Items	86	25	31	111	124
103	28	12	131	86	86	10	Profit before tax	1599	289	176	1888	1504
61	26	6	87	106	106	11	Provision for Taxation :					
10	5	0	15	0	0	12	- Current Tax	103	27	11	130	84
0	10	0	10	0	0		- Deferred Tax	60	25	6	85	106
174	69	18	243	192	192		- Fringe Benefit Tax	10	5	0	15	0
1203	322	44	1525	1027	1179		- Prior Year Tax Adjustments	0	9	0	9	0
15	-16	20	-1	20	20		- Total provision for taxation	173	66	17	239	190
1218	306	64	1524	1047	1199	13	Profit after tax	1426	223	159	1649	1314
314	314	314	314	314	314	14	Adjustments on consolidation	0	0	0	0	0
20.81	5.29	1.51	26.10	18.66	21.08	15	Net Profit	1426	223	159	1649	1314
19.40	4.88	1.02	24.26	16.67	19.09	16	Paid up Equity Share Capital [Face Value Rs. 5 /-]	314	314	314	314	314
						17	Reserves excluding Revaluation Reserve				7049	5830
						18	E P S [Rs.] [For the period - not Annualised]:					
						a	Before extra-ordinary items	24.07	3.95	3.03	28.02	22.90
						b	After extra-ordinary items	22.70	3.55	2.53	26.26	20.93
						19	Aggregate of Non-promoter Shareholding :					
							- Number of Equity Shares	17575229	17575229	17575229	17575229	17575229
							- Percentage of Shareholding	27.98%	27.98%	27.98%	27.98%	27.98%

Note : [#] To give meaningful comparison, the consolidated figures for the previous year ended on March 31, 2005, the reporting period of all the foreign subsidiaries and a joint venture company has been restated to align with that of the reporting period of the Holding Company.



Cadila Healthcare Limited

Registered Office : Zydus Tower , Satellite Cross Roads, Ahmedabad - 380015.
Tel. No. (+91-79) 686 8100 Fax No. : (+91-79) 686 2365/66 Website : www.zyduscadila.com

Audited Financial Results for the Quarter ended 31st March, 2006.

Notes :

- [1] The above audited results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on April 28, 2006.
- [2] The Board of Directors have recommended :
[A] a bonus issue of equity shares, subject to the approval of the shareholders at the forthcoming Annual General Meeting of the Company, in the ratio of ONE equity share of the Company of Rs. 5 /- each for every share held.
[B] a dividend of Rs. 6/- [@ 120 %] per equity share on 62,806,854 equity shares of Rs. 5/- each for the financial year ended March 31, 2006.
- [3] The Company has received approval from the USFDA for two products for ANDAs filed.
- [4] The Company has filed third IND for the new Molecular Entity [NME] - ZYH2 with the Drug Controller General of India.
- [5] The Company has acquired 14.96 % stake in " Carnation Nutra-Analogue Foods Limited " [Carnation], a listed public company through the open market and has made an open offer to acquire additional 20 % shares as per SEBI Regulations. The company has further purchased 8,77,183 equity shares, representing 15.73 % stake from the market till March 31, 2006 as permissible as per SEBI Regulations.
- [6] The Company has decided not to invest in a European Bio-technology business opportunity owing to due diligence proving unsatisfactory.
- [7] In Consolidated Accounts, the accounts of foreign subsidiaries / a Joint Venture Company are audited upto December 31, 2005 / February 28, 2006 and subject to limited review by their auditors for the balance period upto March 31, 2006.
- [8] The status of investor complaints :
Pending at the beginning of the quarter - Nil, received during the quarter - 42, disposed off during the quarter - 42, - pending at the end of the quarter - Nil.
- [9] The Company has one segment of activity viz. " Pharmaceuticals ".

By Order of the Board,
For Cadila Healthcare Limited,

Pankaj R.Patel
Chairman & Managing Director

Ahmedabad, 28th April, 2006.